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Abstract

Objective Bone health in SLE is adversely affected
by vitamin D deficiency, inflammatory cytokines and
glucocorticoid use. We hypothesised that vitamin D
supplementation would increase markers of bone
formation and decrease markers of bone resorption in SLE
subjects.
Methods We studied 43 vitamin D-deficient SLE subjects
who participated in a 12-week randomised controlled
trial of 2000–4000 IU/day vitamin D supplementation
versus placebo. Subjects had inactive SLE (SLE Disease
Activity Index ≤4) and were taking <20 mg prednisone
daily at baseline. We assayed baseline and week 12 serum
25-hydroxyvitamin D, N-terminal propeptide of type 1
collagen (P1NP) and C-telopeptide (CTX). We tested the
effect of vitamin D versus placebo on change (Δ) in P1NP
and ΔCTX in an intention-to-treat analysis. Secondary
analyses evaluated whether vitamin D affected bone
turnover among subjects achieving vitamin D repletion
(≥30 ng/mL) or currently taking glucocorticoids.
Results 28 subjects were randomised to vitamin D
and 15 to placebo. Mean age was 39 years and 40%
were using glucocorticoids at enrolment. Repletion was
achieved by 46% in the vitamin D group versus none in the
placebo group. Changes in bone turnover markers were
not significantly different in the vitamin D group versus
placebo group (median ΔP1NP −0.2 vitamin D group vs
−1.1 placebo group (p=0.83); median ΔCTX +3.5 vitamin
D group vs −37.0 placebo group (p=0.50)). The effect
of vitamin D did not differ based on achieving vitamin D
repletion or baseline glucocorticoid use.
Conclusion Vitamin D supplementation did not affect the
12-week change in bone turnover markers among SLE
subjects in this trial.

Introduction
Poor bone health is common in SLE due to
disease and treatment. Patients with SLE have
twice the fracture risk of individuals without
SLE, and patients with SLE with nephritis
are at even greater risk.1–3 Systemic inflammation, glucocorticoid use, lupus nephritis,
premature menopause and vitamin D deficiency all have deleterious effects on bone
health. Numerous studies have demonstrated
that lower vitamin D levels are associated with

higher SLE disease activity, although trials of
vitamin D supplementation for reducing SLE
disease activity have had conflicting results.4–7
Data on vitamin D supplementation for
bone health in SLE are mostly derived from
observational studies, raising concerns about
confounding by indication; patients with SLE
perceived to be at highest risk for fracture
may be more likely to receive vitamin D.
Circulating vitamin D affects bone metabolism through direct effects on bone and by
influencing intestinal calcium absorption and
parathyroid hormone (PTH) levels.8 Bone
resorption by osteoclasts and bone formation by osteoblasts are coupled, such that an
increase in bone resorption is followed by an
increase in bone formation. The dynamic
processes of bone resorption and formation
can be measured using biomarkers of bone
turnover. The International Osteoporosis
Foundation recommends using N-terminal
propeptide of type 1 collagen (P1NP) as a
marker of bone formation and C-telopeptide (CTX) as a marker of bone resorption
in clinical research.9 In the setting of vitamin
D deficiency, calcium absorption decreases
and PTH level increases, leading to increased
bone resorption paired with increased bone
formation. Vitamin D repletion is expected
to increase calcium absorption and decrease
PTH level, thereby decreasing both bone
resorption (eg, decreasing the level of CTX)
and formation (eg, decreasing the level of
P1NP).
Limited data from cross-sectional studies
in SLE suggests that higher vitamin D levels10
and lower SLE disease activity10 are associated
with higher levels of bone formation markers.
Due to their observational nature, past studies
that focused on vitamin D deficiency in SLE
have been unable to test whether vitamin D
repletion decreases bone turnover.
We investigated the effect of vitamin D
supplementation on changes in bone turnover
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markers in a randomised controlled trial in vitamin D-deficient patients with SLE. We hypothesised that vitamin
D supplementation would lead to a greater decrease in
P1NP and CTX levels compared with placebo.
Methods
Study population
Subjects had completed a randomised, double-blinded,
placebo-controlled trial testing the effect of vitamin D3
supplementation on expression of genes induced by
interferon-alpha (‘interferon gene signature’) in patients
with SLE (NCT00710021).6 The primary outcome was
a reduction in the interferon gene signature at week
12. Fifty-seven SLE subjects were randomised at six US
sites from 2009 to 2011; 54 subjects were included in a
modified intention-to-treat analysis (three subjects never
received a dose of study drug). Stored blood samples
were available for the current study for 43 subjects (28
in vitamin D intervention arms and 15 in placebo arm).
Enrolment criteria
Female and male patients aged ≥18 years who fulfilled
American College of Rheumatology 1997 classification
criteria for SLE were recruited. Vitamin D deficiency
(serum 25-hydroxyvitamin D (25(OH)D) ≤20 ng/mL)
was required. Stable, inactive SLE (Safety of Estrogens in Lupus Erythematosus National Assessment
(SELENA)-SLE Disease Activity Index (SLEDAI) ≤4),11
prednisone <20 mg/day or no prednisone and a stable
immunosuppressant regimen were required. Exclusion
criteria are listed in the online supplementary 1.
Treatment groups
Subjects were randomised 1:1:1 to vitamin D 2000 IU/
day, 4000 IU/day or placebo. Due to limited sample
size, subjects randomised to vitamin D 2000 IU/day or
4000 IU/day were analysed together to maximise statistical efficiency. Treatment adherence was assessed at
week 12: vitamin D repletion (serum 25(OH)D ≥30 ng/
mL) was considered evidence of adherence to vitamin D
or non-adherence to placebo.
Study visits and data collection
Eligibility was confirmed at a screening visit including
a blood draw, medical history, medication review and
physical examination. Study visits at baseline and week
12 included a blood draw, medical history, medication
review, questions about symptoms and physical examination. SLE disease activity was measured at each visit using
the SELENA-SLEDAI, modified to include spot urine
protein/creatinine ratio. Rho, Inc. managed data collection and quality control.
Laboratory evaluation
Serum 25(OH)D was measured in baseline and week
12 samples centrally at the Medical University of South
Carolina (Hollis laboratory) using a radioimmunoassay
(DiaSorin, Stillwater, Minnesota, USA).12
2

Expression of three genes induced by interferon-alpha
(Mx1, Ifit1 and Ifi44) at baseline and week 12 was determined using reverse transcription-PCR (TaqMan assay)
performed at Feinstein Institute for Medical Research
(Diamond laboratory) on whole blood collected using
Pax gene tubes. Interferon gene signature was computed
relative to expression of these genes in healthy controls.6
Bone turnover markers, P1NP and CTX, were measured
at the Brigham and Women’s Hospital Research Assay
Core using excess baseline and week 12 blood samples
that had been stored at −80°C at Feinstein Institute for
Medical Research (Biorepository). P1NP and CTX were
measured in serum with one exception noted in online
supplementary file 2. P1NP was measured by radioimmunoassay (Orion Diagnostics, Finland) with intra-assay coefficient of variation (CV) 3.2%–7.1%. CTX was measured
by immunoradiometric assay (Serum CrossLaps, Arizona,
USA) with intra-assay CV 1.8%–5.0%. See online supplementary 2 for further details.
Statistical analysis
Changes (Δ) in 25(OH)D, P1NP and CTX were calculated as week 12 minus baseline value. We estimated
correlations between baseline 25(OH)D and bone turnover markers, and correlations between Δ25(OH)D and
changes in bone turnover markers, ΔP1NP and ΔCTX,
using Spearman coefficients. Change in 25(OH)D, P1NP
and CTX within each study arm was evaluated using
signed rank tests. We tested the effect of vitamin D supplementation versus placebo on ΔP1NP and ΔCTX using
Wilcoxon rank-sum tests in an intention-to-treat analysis.
We performed several sensitivity analyses testing (1) if
ΔP1NP and ΔCTX differed across the three original study
arms, (2) whether achieving vitamin D repletion versus
not affected changes in bone turnover markers and (3)
the effect of vitamin D in subgroups by baseline glucocorticoid use (any/none) and baseline interferon-alpha
gene signature (detectable/undetectable). The final
sensitivity analysis excluded subjects taking bisphosphonates at baseline.
Analyses were performed using SAS V.9.4. A two-tailed
p value <0.05 was considered statistically significant.
Results
We analysed results from 43 subjects: 28 randomised to
vitamin D (2000 or 4000 IU/day) and 15 randomised to
placebo (see online supplementary 3). Black race, the
presence of a detectable interferon gene signature and
glucocorticoid use were more common among subjects
randomised to vitamin D (table 1).
Among all subjects, baseline 25(OH)D was inversely
correlated with baseline P1NP (r=−0.31, p=0.04) but not
with baseline CTX (r=−0.07, p=0.68). Twelve-week change
in 25(OH)D was not significantly correlated with ΔP1NP
(r=0.003, p=0.99) or ΔCTX (r=0.07, p=0.64).
Vitamin D significantly increased among subjects in the
vitamin D group; subjects in the placebo group also had
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Table 1 Baseline characteristics of SLE subjects in a
randomised trial of vitamin D versus placebo
Vitamin D* (n=28)

Placebo (n=15)

 Age, years

34.5 (29.5–45.0)

37.0 (30.0–50.0)

 Female

92.9

93.3

Demographics

 Race
  
White

32.1

60.0

  
Black

53.6

40.0

  
Other

14.3

0

SLE characteristics
 Disease duration, years

8.0 (3.9–14.2)

10.0 (3.3–16.0)

 ANA positive

96.4

86.7

 Anti-double stranded DNA
positive

92.9

93.3

 Renal disorder

35.7

40.0

 SELENA-SLEDAI score
 Interferon gene signature
detectable

3 (2–4)
89.3

4 (2–4)
73.3

Laboratory values
 CTX, mg/L

80.0 (34.0–118.5)

76.0 (64.0–147.0)

 P1NP, μg/L

45.2 (31.8–62.2)

48.9 (31.5–74.3)

 Serum 25-hydroxyvitamin D,
ng/mL

11.9 (10.1–14.4)

9.9 (6.9–14.5)

Medications
 Glucocorticoids, prednisone equivalent
  
0 mg/day

57.1

66.7

  >0 to <7.5 mg/day

25.0

20.0

  
≥7.5 mg/day

17.9

13.3

 Antimalarial

60.7

80.0

 Azathioprine

25.0

6.7

 Methotrexate

14.3

0

 Mycophenolate

32.1

33.3

 Bisphosphonate

10.7

6.7

Presented as median (IQR) or %.
*2000 IU daily (low dose) or 4000 IU daily (high dose).
CTX, C-telopeptide; P1NP, N-terminal propeptide of type 1 collagen; SELENA-SLEDAI,
Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index.

a significant but smaller increase in vitamin D (figure 1A).
The median increase in 25(OH)D was significantly greater
among subjects in the vitamin D group (16.9 (IQR 13.8–
21.0) ng/mL) than placebo (4.4 (IQR −1.3 to 6.6) ng/
mL) (p<0.01). Median P1NP did not significantly change
between baseline and week 12 in the vitamin D or placebo
group, and the between-group difference was not significant
(figure 1B). Likewise, median CTX was not significantly
different at baseline and week 12 in either group, and the
between-group difference was not significant (figure 1C).
The online supplementary 4 presents individual-level data.
Changes in bone turnover markers were similar in the
three original study arms (table 2). Changes in P1NP and
CTX were similar among 13 subjects who achieved versus
30 who did not achieve vitamin D repletion. In analyses stratified by baseline glucocorticoid use, we did not
observe a difference in ΔP1NP or ΔCTX in the vitamin D

Figure 1 Within-group and between-group change in (A)
25-hydroxyvitamin D (25(OH)D), (B) N-terminal propeptide
of type 1 collagen (P1NP) and (C) C-telopeptide (CTX) from
baseline to week 12.

versus placebo group. Changes in bone turnover markers
did not differ by vitamin D versus placebo group among
subjects with or without a detectable interferon signature at baseline. Results were similar after excluding four
subjects using bisphosphonates at baseline.
Discussion
In this randomised, placebo-controlled trial in vitamin
D-deficient SLE subjects, we observed small changes in
P1NP and CTX at 12 weeks in the vitamin D and placebo
groups. Baseline serum 25(OH)D was inversely associated
with baseline P1NP, but change in 25(OH)D at 12 weeks
was not correlated with change in bone turnover markers.
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Table 2 Sensitivity analyses
Change in P1NP, μg/L
Original study arms
 4000 IU/day (n=16)

1.5 (−13.8 to 4.4)

P value
0.93

Change in CTX, mg/L
9.0 (−43.5 to 74.0)

 2000 IU/day (n=12)

−0.4 (−2.9 to 6.7)

−8.5 (−45.5 to 8.0)

 Placebo (n=15)

−1.1 (−6.8 to 13.0)

−37.0 (−74.0 to 34.0)

P value
0.33

Vitamin D repletion achieved
 Yes (n=13)

1.5 (−0.5 to 5.3)

 No (n=30)

−1.2 (−8.3 to 8.4)

0.40

−3.0 (−48.0 to 10.0)

0.74

−2.5 (−52.0 to 34.0)

Using glucocorticoids at baseline
 Vitamin D (n=12)

−0.4 (−5.1 to 7.1)

 Placebo (n=5)

−1.2 (−6.8 to 3.8)

0.96

8.0 (−35.0 to 15.5)

0.33

−37.0 (−52.0 to −11.0)

Not using glucocorticoids at baseline
 Vitamin D (n=16)

0.6 (−8.6 to 3.8)

 Placebo (n=10)

0.3 (−4.9 to 13.0)

0.73

−1.0 (−58.5 to 43.5)

0.90

−10.0 (−74.0 to 46.0)

Interferon signature detectable at baseline
 Vitamin D (n=25)

−0.5 (−8.3 to 2.2)

 Placebo (n=11)

−1.2 (−6.8 to 13.2)

0.52

1.0 (−48.0 to 14.0)

0.22

−40.0 (−84.0 to 34.0)

Interferon signature undetectable at baseline
 Vitamin D (n=3)
 Placebo (n=4)

15.8 (10.8 to 16.1)

0.16

0.3 (−5.0 to 7.4)

31.0 (−39.0 to 364.0)

0.87

22.0 (−27.0 to 493.5)

Subjects not using bisphosphonates at baseline
 Vitamin D (n=25)
 Placebo (n=14)

0.63

−0.2 (−4.0 to 4.1)
0.3 (−4.9 to 13.0)

6.0 (−39.0 to 17.0)
−38.5 (−74.0 to 34.0)

0.51

P values from Kruskal-Wallis test for three-group comparison and Wilcoxon rank-sum test for two-group comparisons.

Changes in P1NP and CTX were similar in the vitamin
D and placebo groups in analyses stratified by vitamin D
repletion, baseline glucocorticoid use and baseline interferon-alpha gene signature.
Bone turnover markers are useful endpoints for clinical
research studies because they change more rapidly than
bone mineral density in response to bone-active therapies.13 They generally increase or decrease together due
to the homeostatic relationship between bone formation
and resorption. Glucocorticoid use disrupts this homeostasis, leading to predominantly decreased bone formation and possibly increased bone resorption.14 Therefore,
it is possible that the effect of vitamin D on bone turnover markers differs in patients using versus not using
glucocorticoids. We did not observe a differential effect
of vitamin D versus placebo based on glucocorticoid use,
though the small sample size limited our ability to draw
definitive conclusions. See online supplementary 5 for
further context.
Our study had several strengths, including a
randomised, double-blind, placebo-controlled design
among patients with SLE with similar renal function
(serum creatinine ≤1.5 mg/dL), pertinent to P1NP and
CTX assays. All subjects were aged <50 years, corresponding with premenopausal years among female
subjects. We measured P1NP and CTX, the bone turnover
4

markers recommended by the International Osteoporosis
Foundation for use in clinical trials.
Our study had important limitations, including the
short duration and limited sample size. As the study
population was small, the study lacked statistical power
for definitive conclusions. Not all subjects consented to
secondary use of their blood samples and banked blood
sample quantity was insufficient for some; thus, serum
biomarkers from 11 trial participants were not assayed.
Subjects were recruited across all seasons so seasonal
variation in endogenous vitamin D synthesis might have
affected the results, particularly the increase in vitamin D
in the placebo group. Both female and male SLE subjects
were included; sex-based differences in bone metabolism
may have impacted our results. Participants had stable,
inactive SLE and our results may not generalise to patients
with high SLE disease activity.
We did not observe a significant decrease in bone
turnover markers in the vitamin D group compared with
placebo overall or in the small subgroup using glucocorticoids at baseline. However, this subgroup analysis
(and likely the overall analysis) was underpowered due
to small sample size, allowing the possibility that an effect
of vitamin D on bone turnover markers was not observed
even if a true effect exists. We advise that patients with
SLE and their clinicians continue to follow the American
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College of Rheumatology’s Glucocorticoid-Induced Osteoporosis guidelines, which include optimising vitamin D
intake, as the current study was not designed to investigate bone density or fracture outcomes.15 16 A larger,
longer-term trial of vitamin D versus placebo in patients
with SLE—particularly premenopausal women with high
disease activity—using bone mineral density or bone
microarchitecture as outcomes would help guide clinical
care.
Conclusions
In this small randomised trial in vitamin D-deficient
patients with SLE, we did not observe a change in P1NP
or CTX at 12 weeks in subjects randomised to vitamin
D 2000–4000 IU/day versus placebo. Larger trials in
premenopausal, vitamin D-deficient patients with SLE
focused on changes in bone mineral density or bone
microarchitecture could elucidate the effect of vitamin D
supplementation in this population with increased fracture risks.
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